Myriad Genetics Inc (NASDAQ: MYGN) has reported E.P.S. of $-0.75 for its third fiscal quarter (ending September 30) versus $-0.43 for the same period a year ago. Relative to the consensus estimate of $-0.08, this was a shortfall of $-0.67. For the latest four quarters through September 30, E.P.S. were $-3.36 compared to $-0.97 a year ago.
Recent Price Action
Myriad Genetics Inc (NASDAQ: MYGN) stock suffered a large decline of -4.0% on 11/6/23. The stock closed at $16.34. The stock has been weak relative to the market over the last nine months but has risen 17.5% during the last week.
Current PriceTarget Research Rating
MYGN’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to continue to be Value Creation neutral.
Myriad Genetics has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Myriad Genetics has a poor Appreciation Score of 19 and a very low Power Rating of 9, leading to the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment